Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients (SOLAIR)

The SOLAIR study, conducted by RCTs using the French healthcare database system (Système National des Données de Santé (SNDS)), enabled the longitudinal dynamic follow-up of 16,750 adults and 2,453 children with severe asthma treated with omalizumab (Xolair®) over a ten-year period, making it one of the largest cohorts ever studied. It provides an in-depth overview of treatment patterns, persistence, and the dynamics of healthcare consumption.

The results show a reduction in asthma-related hospitalizations (75%) and the use of oral corticosteroids (30%) after two years of treatment, in both adults and children. Additionally, some patients maintain asthma control after discontinuing treatment, with low hospitalization rates and moderate use of corticosteroids.

N° T12944822020012 (https://www.health-data-hub.fr/projets/french-cohort-severe-asthmatic-patients-treated-omalizumab-real-life-settings-solair)

Data Controller : Novartis

Data Processor : RCTs

Comité Scientifique : Arnaud Bourdin, Antoine Deschildre, Marc Humbert, Mathieu Molimard, Camille Taillé